This NL-BI Access Policy (AP) governs the NL-BioImaging infrastructure - a Dutch national infrastructure for advanced light microscopy in life sciences. The NL-BI received funding in 2023 by NWO and involved parties have concluded a consortium agreement (CA) for this signed by all deans and directors. This Access Policy document describes general rules concerning access organisation and management of the NL-BI infrastructure and has been discussed with the Project Management Team (PMT) of NL-BioImaging and the Advisory Board of NL-BI (including directors of other European national BioImaging consortia as well as Euro-BioImaging). Note that the AP is not directly linked to the CA of NL-BI as NL-BI encompasses more than the received funding in 2023, including other NWO-funded microscopy instruments.

NL-BioImaging - Access Policy

Version 1.0 of 24.04.2025

This NL-BI Access Policy governs the NL-BioImaging ('NL-BI') Infrastructure and covers the following subjects: governance structure, application procedure, complaints procedure, financial arrangements, warranties.

Furthermore, the Parties wish to specify their respective rights and obligations in relation to the NL-BI Infrastructure and wish to lay down general rules concerning the organisation and the management of the NL-BI Infrastructure.

Now, therefore, it is hereby agreed as follows:

1. **Definitions**

"Access Policy" means this Access Policy between Parties including all Annexes;
"Annex" means an annex to this Access Policy;
"Applicable law" means all such (inter)national, European, local and other laws, rules and regulations that are applicable to the performance of NL-BI infrastructure;
"Contact Person" means the person appointed by the Core Facility to regulate the application procedure, as listed in Annex 2;
"Core facility" means the facility and/or institute of a Party where the Equipment is stationed;
"**Employed**" means a legal relationship between a natural person and a Party as a result of an employment contract, internship agreement or any similar type of agreement which arranges the rights and obligations to perform research related activities on the premises of a Party or on behalf of such Party;
"Euro-BioImaging" means Euro-BioImaging European Research Infrastructure;
"Equipment" means the equipment which is subject to this Access Policy as set out in Annex 2;
"Party or Parties" means a Party or the Parties part of the NL-BI Infrastructure as set out in Annex 1;
"Project Management Team" means the consortium body as described in article 3.1;
"**Project Manager**" means the consortium body (person) as described in article 3.1;
"National Steering Committee" means the consortium body as described in article 3.1;
"Nodes" means the seven nodes of the NL-BI Infrastructure as described in Annex 2;
"Node Leader" means the leaders of the seven nodes of the NL-BI Infrastructure as

described in Annex 2;
"Users" means users of the Equipment of the NL-BI Infrastructure that are divided in two categories:
a) **Internal Users** means users Employed by a Party where the Equipment is stationed; or
b) **External Users**, means users not Employed by the Party where the Equipment is stationed.

2. **Purpose, principles and subject matter of the Access Policy**

2.1. The purpose of this Access Policy is to govern the NL-BI Infrastructure to ensure open access to the most advanced microscopy techniques for the broad life sciences community, and the relationship among the Parties, in particular concerning the management of the NL-BI Infrastructure and the rights and obligations of the Parties.

2.2. Each Party undertakes to every other Party to use reasonable endeavours to perform and fulfil, promptly, actively and on time, all its obligations under this Access Policy.

2.3. Parties shall manage the NL-BI Infrastructure in accordance with Applicable law, this Access Policy and taking into account the criteria and standards applicable to scientific research.

2.4 It is understood between the Parties that where this Access Policy grants any rights and/or imposes any obligations on a Core Facility, the Party of which such Core Facility is a part of shall be bound by such rights and/or obligations.

2.5 Each Core Facility shall ensure that the Equipment purchased as part of the NL-BI Infrastructure shall be available for External Users at least fifty percent (50%) of the time. This percentage shall be calculated on a half-year basis to ensure fair access time throughout the year. If a Core Facility has allocated less than fifty percent (50%) of the available slots to External Users, the Core Facility must show that it has acted within reason of doing so. In the half-year report each Core Facility will be asked to confirm (by means of a tick box) that up to 50% of its capacity was available for External users in previous 6 months.

2.6 The Parties shall provide the Project Manager with financial, personnel, scientific, and progress reports regarding the NL-BI Infrastructure every six (6) months (at the beginning of January and July of each year). Such reports shall be drafted in accordance with the guidelines of the Project Management Team, and with the requirements from NWO.

3. **Governance structure**

3.1. The organisational structure of the NL-BI Infrastructure shall comprise of:
- the National Steering Committee, which consists of a representative of each Party;
- the Project Management Team, which consists of a minimum of three representatives from the Parties elected by the National Steering Committee;
- the Project Manager, a representative appointed by the Project Management Team.

3.2. National Steering Committee

3.2.1. The National Steering Committee shall be the ultimate governing body of the NL-BI infrastructure. This means that it will decide on all matters relating to the NL-BI infrastructure, unless otherwise agreed in the NL-BI Access Policy.

3.2 As such, the National Steering Committee shall be responsible for deciding on all matters relating to the NL-BI infrastructure including, but not limited to:
- Approval of changes to this NL-BI Access Policy;
- Nomination and election of members of the Project Management Team;
- Installation of external advisory boards and the appointment of their members;
- Addition of new nodes;
- Election of national node leaders;
- Accession of new Parties.

3.2.3. The National Steering Committee shall meet at least once (1) a year.

3.2.4. The National Steering Committee shall decide with a simple majority, unless a subject requires an unanimous decision. For each decision to be validly taken a required quorum of a majority of the Parties is required as well. At least Accession of new Parties and approval of changes to this NL-BI Access Policy requires an unanimous decision.

3.3. Project Management Team

3.3.1 The Project Management Team shall be the executive body of the NL-BI Infrastructure and shall be responsible for:
- Formulating proposals to the National Steering Committee;
- Identification and handling of technical and organizational problems;
- Monitoring of the activities of the NL-BI Infrastructure;
- Implementing changes in activities within the NL-BI infrastructure, including the addition of new Nodes;
- Appointing the Project Manager;
- Defining the tasks and responsibilities of the Project Manager;
- Approving pricelists of the Core Facility or any changes to the pricelists made by a Core Facility, which approval shall not be unreasonably withheld;
- Handling complaints from Parties or Users; and
- Deciding on applications in accordance with article 4.3.

3.3.2. The Project Management Team shall decide with a majority and a required quorum of a majority as well.

3.4. Project Manager

3.4.1. The Project Manager shall be responsible for:
- Managing the central applications for use of the NL-BI Infrastructure;
- Monitoring the usage of the NL-BI Infrastructure on the basis of the 6 months reports;
- Drafting reports on the usage of the NL-BI Infrastructure;
- Communication between the different stakeholders.

4. Application procedure

4.1. Application procedures

4.1.1. To gain access to the NL-BI Infrastructure Users can follow one of the three types of application procedures:
a) the local procedure, as described in article 4.2;
b) the central procedure, as described in article 4.3;
c) the Euro-BioImaging procedure, as described in article 4.4.

4.1.2. If the application has led to admittance of an applicant following one of the procedures mentioned under a), b) or c), Parties will arrange the matters as set out in article 4.5.

4.2. The local procedure.
The local procedure is exclusively available to Internal Users. The written application shall be submitted to the Core Facility and shall be subject to approval by the head of the Core Facility. The Contact Person of the Core Facility shall inform the applicant about admittance or refusal. If admitted, the Contact Person of the Core Facility shall guide the applicant to the specific instrument and operator and register the access using the NL-BI template form for access. If the application has been refused, the Contact Person of the Core Facility will inform the applicant accordingly stating the reasons for refusal and forward the request to NL-BI via email to *nl-bi@amsterdamumc.nl*.

4.3. The central procedure. The applicant submits the filled-in online application form, attached as Annex 4, to the NL-BI portal. The Project Manager reviews whether the application is eligible and if so, registers the application and sends the applicant a confirmation of receipt. The application will be subject to approval by the Project Management Team. The Project Manager shall inform the applicant about admittance or refusal. If admitted, the Project Manager shall guide the applicant to the appropriate Core Facility. If the application has been refused, the Project Manager will inform the applicant accordingly stating the reasons for refusal.

4.4 The Euro-BioImaging procedure. The applicant submits the filled-in application form to the Euro-BioImaging portal (see 'How to Access' on the website of Euro-Bioimaging), which includes the NL-BioImaging node. The Euro-BioImaging staff provides scientific and technical advice to the access request. Once the access proposal request is granted, the applicant will be contacted by the involved Node to settle the practicalities for access, such as planning the visit. If the Node for whatever reason cannot provide access to the requested facilities, the Node shall inform the applicant accordingly stating the reasons therefore.

4.5. After admitting the application and redirecting the User to the appropriate Core Facility, the Contact Person of the Core Facility will:
- provide a quote to the User for access to the Equipment and/or performance of the requested services;
- draft a service agreement, including the quote, and local ethical guidelines to be followed to be signed by the User and the Core Facility
- send the executed copy of the service agreement to the Project Manager.

5. Publication & FAIR Data

5.1 Open Access Publications. All scientific publications relating to the NL-BI Infrastructure must be made available for Open Access, following the NWO Open Access Policy. Publications should mention the full project name (NL-BioImaging) and number (184.036.012) to allow traceability. It is suggested that this information is included in the application procedure and/or service agreement in line with the example below:

- All publications produced by means of the NL-BI infrastructure need to be emailed to nl-bi@amsterdamumc.nl. Acknowledgements must be as follows: "Part of the work has

been enabled by the NL-BioImaging infrastructure sponsored by NWO National Roadmap for Large-Scale Research Infrastructure (NWO 184.036.012).

5.2 FAIR Data. NL-BioImaging is a FAIR data infrastructure. Users must follow NWO guidelines on research data management. Data from publications generated using NL-BioImaging facilities should therefore be submitted to a trusted bioimaging repository, namely the BioImage Archive (https://www.ebi.ac.uk/bioimage-archive/), or the Image Data Resource (https://idr.openmicroscopy.org/), such that the data are Findable Accessible, Interoperable and Reusable.
See *Annex 4: NL-Bioimaging Data Management & Sharing Policy* for a complete overview.

6. **Complaints procedure**

6.1. The NL-BioImaging parties shall endeavour to settle disputes or complaints from each other or Users amicably. Parties agree that if the Core Facility is first addressed, the Core Facility is the most suitable Party to handle complaints from Users. If parties cannot settle disputes by themselves, they will reach out to the Project Management Team for support.

6.2. Any claims, controversies or disputes arising out of or in connection with this Access Policy which cannot be settled amicably between the Parties or cannot be resolved by the Project Management Team, shall be subject to the exclusive jurisdiction of the competent court in the Netherlands.

7. **Financial arrangements**

7.1 Each Core Facility shall be solely responsible for any financial matters related to the Equipment stationed at their Core Facility and their obligations under this Access Policy. This includes, but is not limited to, the obligation of the Core Facility to ensure that it has sufficient funds to operate and have the Equipment maintained following industrially and scientifically recognized standards and that repairs can be performed as quickly as possible. Furthermore, the Core Facility shall use reasonable efforts to reserve funding for replacing the Equipment when it is considered 'End of Life' or to transfer the Equipment to another Core Facility or (sub)Node.

7.2 Each Core Facility shall generate a pricelist for the services. Each Core Facility shall ensure that its prices will not impede the scientific community's access to its Equipment. Furthermore, a Core Facility should not discriminate in its pricing between research organisations. However, a Core Facility has to charge full cost rate prices to commercial organisations. Each Core Facility is always free to offer to users a free pilot for the purpose of conducting preliminary testing as proof of concept of the experiment users intend to conduct.

7.3 Partial subsidized cost model: Academic Users should pay a user fee based on a partial cost model, which may differ between institutes but should be ranging from no charge to a maximum of 50% of the full cost (depreciation, maintenance costs, operating costs, etc.). The Core Facility will determine prices of the NL-BI subsidized infrastructure in accordance with this article 7 A clear overview of fees-for usage should be shown on the website of the Core Facility.

8. **Warranties & Liability**

8.1 Each Party shall indemnify each of the other Parties, their directors, officers, employees, affiliates and subcontractors (the 'Indemnified Parties') for any damages resulting from third party claims arising out of that first Parties' activities to be carried out pursuant to that Party's obligations under this Agreement. This indemnification clause will not apply to the extent that the claim has arisen as a result of the Indemnified Party's gross negligence or wilful misconduct.

8.2 The Parties agree that to the maximum extent permitted by applicable laws and regulations, in no event shall a Party (including its affiliates and subcontractors, and their respective directors, officers and employees) be liable to the other Parties in contract or otherwise howsoever arising or whatever the cause thereof, for any indirect damages of any nature, including but not limited to any loss of profit, business, goodwill, reputation, contracts, revenues or anticipated savings or business opportunities.

8.3 Any liability is legally embedded in each core facility (similar to all instruments in a core facility).

9. Term, termination & accession

9.1 Term. The Access Policy shall come into effect on the date the Access Policy has been approved by the National Steering Committee ("Effective Date") and shall continue to be in effect until, the Parties determine that the NL-BI Infrastructure must be dissolved.

9.2 Termination. Upon termination, the National Steering Committee shall prepare a proposal that includes at least an accountability statement to the funding party, if applicable, and distribution of the Equipment and funds. As soon as the Equipment has been fully depreciated, it shall become the sole property of the Core Facility that has procured it. Any and all rights and obligations relevant to the Equipment from this Access Policy shall at that moment cease to have effect. For the avoidance of any doubt, the Equipment shall not be considered fully depreciated earlier than 10 years after purchase of the Equipment.

9.3 If any Party commits any breach of or is in default of any of the terms or conditions of this Access Policy and fails to remedy such default or breach within thirty (30) days after the receipt of written notice from the Chair of the Project Management Team, the National Steering Committee may terminate the participation of such Party to the NL-BI Infrastructure. Upon termination, all Equipment stationed at such Party shall be redistributed amongst the other Parties by the National Steering Committee, and the receiving party shall compensate for the remaining part (i.e., fraction of 10 years remaining) of the

9.4 If a Party may terminate its participation in the NL-BI Infrastructure, it will inform the Chair of the Project Management Team of its intention. The withdrawing Party and the National Steering Committee shall in good faith discuss the consequences of such withdrawal. The foregoing provided that withdrawing Partner shall continue to grant access under this Access Policy with respect to the Equipment for the purpose of completing applications approved prior to the termination date.

9.5 Accession. A new entity becomes a Party to this Access Policy upon unanimous approval from the National Steering Committee. Such accession shall have effect from the date

communicated via email by the Project Manager and as part of the shared NSC meeting minutes.

10. Ancillary Documents. The following attachments form an integral part of the NL-BI Access Policy:

Annex 1: List of Parties to the Access Policy

Annex 2: Description of the Nodes/Core Facilities and the equipment that are subject to this Access Policy.

Annex 3: Application Form

Annex 4: NL-Bioimaging Data Management & Sharing Policy

ANNEX 1

List of Parties to the Access Policy

1) **Stichting Amsterdam UMC**, having its principal place of business at De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands, hereby represented by its fully owned subsidiary Amsterdam UMC Research B.V., hereinafter also referred to as "**Amsterdam UMC**";

2) **Universiteit van Amsterdam**, having its principal place of business at Science Park 904, 1098 XH Amsterdam, the Netherlands, hereinafter also referred to as "**UvA**";

3) **Erasmus University Medical Center Rotterdam**, an institution organized in accordance with public law of the Netherlands (article 1.13,2 WHW), having its principal place of business at Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands, acting exclusively for and on behalf of its Departments of Pathology and its Core Facility Erasmus Optical Imaging Centre, hereinafter also referred to as "**Erasmus MC**";

4) **Leiden University**, having its principal place of business at Rapenburg 70, 2311 EZ Leiden, the Netherlands, acting exclusively for and on behalf of its Department Leiden Academic Centre for Drug Research (LADCR), hereinafter also referred to as "**LU**";

5) **Academisch Ziekenhuis Leiden**, acting under the name Leiden University Medical Center (LUMC), having its principal place of business at Albinusdreef 2, 2333 ZA Leiden, the Netherlands, hereinafter also referred to as "**LUMC**";

6) **Maastricht University**, having its principal place of business at Minderbroedersweg 4-6, 6211 LK Maastricht, the Netherlands, acting exclusively for and on behalf of its Faculty of Health, Medicine and Life Sciences, hereinafter also referred to as "**UM**";

7) **Rijksuniversiteit Groningen**, having its principal place of business at Broerstraat 5, 9712 CP Groningen, the Netherlands, hereinafter also referred to as "**RUG**";

8) **Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis**, having its principal place of business at Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands, hereinafter also referred to as "**NKI-AVL**";

9) **Stichting Radboud Universitair Medisch Centrum**, having its principal place of business at Geert Grooteplein 10, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands, hereinafter also referred to as "**RUMC**";

10) **Technische Universiteit Delft**, an institution organized in accordance with public law of the Netherlands (article 1.13,2 WHW), having its principal place of business at Stevinweg 1, 2628 CN Delft, the Netherlands, acting exclusively for and on behalf of its Faculty of Applied Sciences, having an office at Lorentzweg 1, 2628 CJ Delft, hereinafter also referred to as "**TU Delft**";

11) **University Medical Center Groningen**, a not for profit educational and research organisation established by virtue of the higher education and research act (Wet Hoger Onderwijs en Wetenschappelijk Onderzoek) having its principal office at Hanzeplein 1, Groningen 9713 GZ, the Netherlands, registered with the Chamber of Commerce (*Handelsregister*) under number 01169570, lawfully represented by a member of its Board of Directors on behalf of its Department of Biomedical Science of Cells and Systems, hereinafter also referred to as "**UMCG**";

12) **University Medical Center Utrecht,** a legal entity existing under the laws of the Netherlands and governed by public law by virtue of the Dutch 'Wet op het hoger onderwijs en wetenschappelijk onderzoek' (Higher Education and Academic Research Act'), having its principal place of business at Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands, hereinafter also referred to as **"UMCU"**;

13) **Universiteit Utrecht**, a legal entity established under the laws of the Netherlands and governed by public law under section 1.8 of the Higher Education and Research Act (*Wet op het hoger onderwijs en wetenschappelijk onderzoek*) and having its registered offices at Heidelberglaan 8, Utrecht, the Netherlands, for the benefit of the Faculty of Science, hereinafter also referred to as "**UU**";

14) **Wageningen University**, an institution organized in accordance with public law of the Netherlands (article 1.13,2 WHW), having its principal place of business at Stippeneng 2, 6708 WE Wageningen, the Netherlands, acting exclusively for and on behalf of its Departments Agrotechnology and Food Sciences, hereinafter also referred to as "**WU**";

15) **Prinses Máxima Centrum voor Kinderoncologie B.V.**, having its principal place of business at Heidelberglaan 25, 3584 CS Utrecht, the Netherlands, hereinafter also referred to as "**PMC**";

16) **Vrije Universiteit**, having its principal place of business at De Boelelaan 1105, 1081 HV Amsterdam, the Netherlands, hereinafter also referred to as **"VU"**;

17) **Universteit Twente,** Faculty of Science and Technology, having its principal place of business at Drienerlolaan 5, 7522 NB Enschede, the Netherlands, duly represented by J.W.F. Timmerman, Managing Director of the Faculty of Science and Technology, hereinafter also referred to as **"UTwente"**;

18) **Hubrecht Instituut**, having its principal place of business at Uppsalalaan 8, 3584 CT Utrecht, the Netherlands, hereinafter also referred to as **"HI";**

19) **Technische Universiteit Eindhoven**, having its principal place of business at Groene Loper 5, 5612 AE Eindhoven, the Netherlands, hereby represented by its research institutes the Institute for Complex Molecular Systems (ICMS) and the Laboratory for Cell and Tissue and Engineering (LCTE), hereinafter also referred to as **"TU/e"**;

ANNEX 2

Description of the Nodes/Core Facilities and the equipment that are subject to this Access Policy

A complete list of equipment will be included in the NL-BioImaging website. The list will be updated regularly.

ANNEX 3

Application Form

Here is a copy of the application form. It will be shared with all facilities as a separate document, as well as included in the NL-BioImaging website.

SUBMIT YOUR PROJECT – GET EXPERT ADVICE

By filling in this form, NL-BI experts will advise you on what bioimaging technologies are optimal for your projects and coordinate access to national or international facilities.

Research Project Title (*required)

- *Add here*

Name and e-mail of the researcher (*required)

- *Add here*

Name and e-mail of the group leader/ PI (or supervisor) (*required)

- *Add here*

Affiliation (required)

- *Add here*

Are you representing a private company or industry user? (*required) (if yes you can write the words "industry user" in the fields where you do not wish to disclose details)

- Yes
- No

Brief description of the project and proposed work to be conducted (max. 200 words) (*required)

- *Add here*

Are there biological/ chemical or other hazards associated with the project? (*required)

Are there any ethical/ GGO or other licenses needed?

- No, not needed
- Yes: already acquired
- Yes: in progress
- Add any other necessary information: ….*add here*

Select the name of the node you request access to (if known):

- Node 1: Probes for functional imaging (PFI)"
- Node 2: 3D Functional Imaging (3D-FI)"
- Node 3: Phenotypic high-throughput microscopy (HTM)"
- Node 4: Bridging scales: Intravital microscopy (IVM)"
- Node 5: Correlated light & electron microscopy (CLEM)"
- Node 6: Smart Microscopy (SM)
- N7 Data management & analysis (DMA)
- I do not know yet, need NL-BI for guidance

List of additional resources that may be required at the facility (Select multiple if needed)

- .. Training in Infrastructure use
- .. Technical assistance to run instrument
- .. Data processing and Analysis
- .. Training workstations
- .. Biobank, biological material storage and processing
- .. Instruments
- .. Animal facilities
- .. Animal preparation

Expertise level in using the selected technology (select)

- First time, require training to use technology
- Working knowledge but need assistance
- Expertise in technology, do not require training

Additional comments or remarks?:

…

SUBMIT

Note:

1. Costs will be charged as will be discussed in an intake meeting
2. Always acknowledge: All publications will be emailed to NL-BI (nl-bi@amsterdamumc.nl). An annual progress report will be given. Depending on microscopes used, acknowledgements must be as follows: *"Part of the work has been performed in the XXXXXXXX Imaging Center, sponsored by NL-BioImaging: NWO 184.036.012*
3. ***Data –*** *Raw data will be available open access after the first publication of a project in consultation with NL-BI*

NL-BioImaging Infrastructure has received funding from the Netherlands Organization for Scientific Research (NWO)

ANNEX 4

NL-BioImaging Data Management & Sharing Policy

NL-Bioimaging users are required to adhere to the NWO Research Data Management policies on FAIR and Open Science (Research data management | NWO). Specifically, researchers are required to:

- ensure data and other research assets (e.g. image analysis code and workflows) are "as open as possible and as closed as necessary"
- carefully manage all research data in accordance with the FAIR Principles
- preserve data for at least ten years, unless legal provisions or discipline-specific guidelines dictate otherwise,
- share data that underlie research publications by depositing them in a trusted repository.

To fulfil the conditions above, NL-Bioimaging users should:

1. *Deposit Data in public repositories*

Note that if you know the data and metadata requirements of the repository beforehand, it is easier to ensure you generate, store and annotate your data in a suitable way.

We recommend you select dedicated imaging repositories:

a. BioImage Archive (https://www.ebi.ac.uk/bioimage-archive/). A dedicated repository for all published image data.

b. Image Data Resource (https://idr.openmicroscopy.org/), which supports reference image data sets, according to the Euro-BioImaging - Elixir Image Data Strategy)

c. EMPIAR (https://www.ebi.ac.uk/empiar/) and EMDB (https://www.ebi.ac.uk/emdb/). Resources for Electron Microscopy Images

d. BioStudies (https://www.ebi.ac.uk/biostudies/). A more general repository for publishing biological studies. If you have experiments where imaging data is generated alongside other types of data, you may wish to consider this option.

These repositories are included in the ELIXIR Deposition Databases for Biomolecular Data. They provide deposition free of charge in most cases.

2. *Deposit Data in Formats that are Accessible to the Community for Reuse*

Bioimage data is generated in a large number of proprietary formats. Some vendors provide open source libraries for parsing their proprietary formats, so they are more widely accessible. Bio-Formats maintains a library of more than 150 different translators.

If you do not need to preserve your original file format, we recommend permanent conversion into a common open format (also developed by the Open Microscopy Environment): OME-TIFF or OME-Zarr (https://doi.org/10.1007/s00418-023-02209-1).

3. *Deposit Data with Sufficient Metadata*

To deposit data, you need to follow community recommendations on how to describe your imaging experiments. For Bioimaging data, the REMBI guidelines should be followed (https://www.nature.com/articles/s41592-021-01166-8). If you would like help to develop REMBI-compliant metadata templates for a specific type of imaging, please get in touch with the NL-Bioimaging National DMA team.